Tolerability of extended duration intravenous Milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors

American Journal of Cardiology

Volumn 84, Issue 8, 1999, Pages 894-899

  Milfred Laforest, Sherry K ^a   Shubert, Joanne ^c   Mendoza, Bernardo ^b   Flores, Isabella ^b   Eisen, Howard J ^a,b   Piña, Ileana L ^b,c  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; MILRINONE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HOSPITALIZATION; HUMAN; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TACHYCARDIA; TITRIMETRY;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MILRINONE; PHOSPHODIESTERASE INHIBITORS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0032864149     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00461-0     Document Type: Article

References (29)

1. Honerjager P. Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J. 121:1991;1939-1944.
2. Cusick D, Pfeifer P, Quigg R. Intravenous milrinone facilitates the initiation of high dose ACE inhibitor therapy and improves prognostic indicators in patients evaluated for cardiac transplantation. (abstr) J Heart Lung Transplant 1996;15:s85.
3. Varriale P., Ramaprasad S. Short-term intravenous milrinone for severe congestive heart failure the good, bad, and not so good . Pharmacotherapy. 17:1997;371-374.
4. Packer M., Carver J., Rodeheffer R., Ivanhoe R., DiBianco R., Zeldis S., Hendrix G., Bommer W., Elkayam U., Kukin M., et al. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
5. Canver CC, Cooler SD. The efficacy of intravenous milrinone in status I cardiac transplant patients (abstr). Am Soc Transpl Physi 1996:206.
6. Skoyles J., Sherry K., Price C. Intravenous milrinone in patients with severe congestive heart failure awaiting heart transplantation. J Cardiothoracic Vasc Anesth. 6:1992;222-225.
7. Mehra M., Ventura H., Kapoor C., Stapleton D., Zimmerman D., Smart F. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol. 80:1997;61-64.
8. Steimle A., Stevenson L., Chelminsky-Fallick C., Fonarrow G., Hamilton M., Moriguchi J., Kartashov A., Tillisch J. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 96:1997;1165-1172.
9. Cody R., Haas G., Binkley P., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
10. Cushman D, Wang F, Grover G, Harvey C, Scalese R, Mitch S, DeForrest J. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28:115s-31s.
11. Konstam M, Dracup K, Baker D, Bottorff M, Brooks N, Dacey R, Dunbar S, Jackson A, Jessup M, Johnson J, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical practice guideline No. 11. AHCPR Publication No. 94-0612. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Dept. Health and Human Services, 1994:98.
12. Voelker J., Cartwright-Brown D., Anderson S., Leinfelder J., Sica D., Kokko J., Brater D. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int. 32:1986;572-578.
13. Woolfrey S., Hegbrant J., Thysell H., Fox P., Lendrem D., Lockwood G., Lasher K., Rogers J., Greenslade D. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal dysfunction. J Pharm Pharmacol. 47:1995;651-655.
14. Franciosa J., Wilen M., Ziesche S., Cohn J. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic cardiomyopathy. Am J Cardiol. 51:1983;831-836.
15. Cooper R., Ghali J., Simmons B., Castner A. Elevated pulmonary artery pressures an independent predictor of mortality . Chest. 99:1991;1348-1354.
16. Bourge R., Naftel D., Costanzo-Nordin M., Kirklin J., Young J., Kubo S., Olivari M., Kasper E. Pretransplantation risk factors for death after heart transplantation a multiinstitutional study . J Heart Lung Transplant. 12:1993;549-562.
17. Costard-Jackle A., Fowler M. Influence of preoperative pulmonary artery pressures on mortality after heart transplantation testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high-risk group . J Am Coll Cardiol. 19:1992;48-54.
18. Murali S., Uretsky B., Reddy P., Tokarczyk T., Betschart A. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation comparative effects of various pharmacologic agents . Am Heart J. 122:1991;1375-1378.
19. Seino Y., Momomura S., Takano T., Hayakawa H., Katoh K. Multicenter, Double-blind, study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med. 24:1996;1490-1497.
20. Pflugfelder P., O'Neill B., Ogilvie R., Beanlands D., Tanser P., Tihal H., Mizgala H., Fitchett D., Kostuk W. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure. Can J Cardiol. 7:1991;5-10.
21. Konstam M., Cody R. Short term use of intravenous milrinone for heart failure. Am J Cardiol. 75:1995;822-826.
22. Cody R., Muller F., Kubo S., Rutman H., Leonard D. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation. 73:1986;124-129.
23. Watson D., Sherry K., Weston G. Milrinone, A bridge to heart transplantation. Anaesthesia. 46:1991;285-287.
24. DiBianco R., Shabetai R., Kostuck W., Moran J., Schlant R., Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New Engl J Med. 320:1989;677-683.
25. Dies F, Krell M, Whitlow P, Liang C, Goldenberg I, Applefeld M, Gilbert E. Intermittent dobutamine in ambulatory outpatients with chronic heart failure (abstr). Circulation 1986;74:II-38.
26. Cesario D., Clark J., Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure a preliminary study . Am Heart J. 135:1998;121-129.
27. Marius-Nunez A.L., Heaney L., Fernandez R.N., Clark W.A., Ranganini A., Silber E., Denes P. Intermittent inotropic therapy in an outpatient setting a cost-effective therapeutic modality in patients with refractory heart failure . Am Heart J. 132:1996;805-808.
28. Packer M., Medina N., Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe congestive heart failure. Circulation. 70:1984;1038-1047.
29. Cuffe M, Califf R, Adams K, Bourge R, Colucci W, Massie B, O'Connor C, Pina I, Quigg R, Silver M, et al. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J; in press.